Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg and primary investigator of the GOBLET trial commented, "I have been pleased to observe the strength of the clinical response data for pelareorep in multiple cohorts of the GOBLET gastrointestinal study, especially in pancreatic and anal cancer. mFOLFIRINOX is currently considered the best treatment option for many pancreatic cancer patients. Therefore, the evaluati ...